Clinical Trials Administrator Archives – November 1, 2003
November 1, 2003
View Issues
-
Compensation for subjects is fine as long as it doesn’t cross the line
In November, national news outlets reported on Steve Rucker, a nurse at the National Institutes of Health and one of two people to receive an experimental vaccine for Ebola. He did it, he told reporters, because he knew how important vaccines were to areas of the world where medicines and expertise for treating diseases are hard to come by. -
Pfizer’s Study Participant Compensation Policy
Pfizers Study Participant Compensation Policy -
Is accreditation the next big thing?
If you look on the web site of the Association for the Accreditation of Human Research Protection Programs (AAHRPP), youll find a half-dozen reasons for why organizations that are involved in human research should consider going through the lengthy accreditation process. -
Special committee looks at subject protections
The newly formed Secretarys Advisory Committee on Human Research Protection has its work cut out committee members already have three subcommittees establishing work plans, and there many more top priorities to be chosen from the federal regulations. -
Research with children raises ethical questions
In recent years, changes in federal law and guidelines on federally funded research have encouraged the inclusion of children as research subjects in clinical drug trials. -
News Brief
Electronic labeling of drug info new must